Retz, M., & Teber, D. (2019). SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11). European journal of cancer, 107, . https://doi.org/10.1016/j.ejca.2018.11.001
Chicago-Zitierstil (17. Ausg.)Retz, Margitta, und Dogu Teber. "SWITCH II: Phase III Randomized, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-pazopanib Versus Pazopanib-sorafenib in the Treatment of Advanced or Metastatic Renal Cell Carcinoma (AUO AN 33/11)." European Journal of Cancer 107 (2019). https://doi.org/10.1016/j.ejca.2018.11.001.
MLA-Zitierstil (9. Ausg.)Retz, Margitta, und Dogu Teber. "SWITCH II: Phase III Randomized, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-pazopanib Versus Pazopanib-sorafenib in the Treatment of Advanced or Metastatic Renal Cell Carcinoma (AUO AN 33/11)." European Journal of Cancer, vol. 107, 2019, https://doi.org/10.1016/j.ejca.2018.11.001.